Monday, January 06, 2020 9:37:09 PM
..................................
• Savara Inc. has raised about $26.8 million as it develops drugs to treat rare lung diseases. The Austin-based pharmaceutical company announced Dec. 20 it intended to sell more than 9.5 million shares of common stock and pre-funded warrants to buy more than 5.7 million shares in a private placement with "institutional investors," which would generate the $26.8 million, although Savara (Nasdaq: SVRA) still needs to deduct placement agent fees and other offering expenses. The company filed securities paperwork Jan. 2 indicating it had raised the $26.8 million from 18 investors. Savara said Dec. 20 it has also agreed to sell warrants that could allow investors to buy more than 32.5 million additional shares of common stock. The warrants can be exercised by investors two years after the close of this private placement or 30 days after Savara achieves a certain clinical milestone, whichever is earlier. That sale could raise gross proceeds of $48.2 million, according to the company, before deducting expenses and fees. Bain Capital Life Sciences led the placement and Ricky Sun of Bain Capital has joined Savara's board of directors. Investors in the private placement included EcoR1 Capital LLC and Logos Capital. Founded in 2008, Savara is led by CEO Rob Neville and develops drugs for orphan lung diseases such as autoimmune pulmonary alveolar proteinosis and nontuberculous mycobacteria.
https://www.bizjournals.com/austin/news/2020/01/06/in-the-money-jan-6-drug-burger-makers-report.html?ana=yahoo&yptr=yahoo
GO SVRA
"PEACE"
Recent SVRA News
- Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 • Business Wire • 04/08/2024 12:05:00 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 03/22/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:26:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:05:33 PM
- Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update • Business Wire • 03/07/2024 09:05:00 PM
- Savara to Present at the Barclays 26th Annual Global Healthcare Conference • Business Wire • 03/06/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 01:31:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:35:51 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:15:14 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:00:11 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 01:01:53 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 02/02/2024 01:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/01/2024 08:50:25 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/31/2024 07:08:28 PM
- Savara to Present at Two Upcoming Healthcare Conferences • Business Wire • 01/31/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:06:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 01:00:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:35:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:34:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:33:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/28/2023 09:29:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/28/2023 09:15:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/28/2023 09:10:13 PM
- Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 12/21/2023 01:05:00 PM
- Savara Added to the NASDAQ Biotechnology Index • Business Wire • 12/20/2023 01:05:00 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM